318 related articles for article (PubMed ID: 30947167)
1. Role of Ancillary Techniques in Thyroid Cytology Specimens.
Nishino M; Krane JF
Acta Cytol; 2020; 64(1-2):40-51. PubMed ID: 30947167
[TBL] [Abstract][Full Text] [Related]
2. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.
Nikiforova MN; Lepe M; Tolino LA; Miller ME; Ohori NP; Wald AI; Landau MS; Kaya C; Malapelle U; Bellevicine C; Troncone G; Nikiforov YE; Baloch Z
Cancer Cytopathol; 2021 Jan; 129(1):33-42. PubMed ID: 32697051
[TBL] [Abstract][Full Text] [Related]
3. Molecular Testing of Thyroid Nodules: A Review of Current Available Tests for Fine-Needle Aspiration Specimens.
Zhang M; Lin O
Arch Pathol Lab Med; 2016 Dec; 140(12):1338-1344. PubMed ID: 27557410
[TBL] [Abstract][Full Text] [Related]
4. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
[TBL] [Abstract][Full Text] [Related]
5. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
[TBL] [Abstract][Full Text] [Related]
6. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.
Lastra RR; Pramick MR; Crammer CJ; LiVolsi VA; Baloch ZW
Cancer Cytopathol; 2014 Oct; 122(10):737-44. PubMed ID: 25123499
[TBL] [Abstract][Full Text] [Related]
7. Molecular cytopathology for thyroid nodules: A review of methodology and test performance.
Nishino M
Cancer Cytopathol; 2016 Jan; 124(1):14-27. PubMed ID: 26348024
[TBL] [Abstract][Full Text] [Related]
8. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
Gortakowski M; Feghali K; Osakwe I
Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
[No Abstract] [Full Text] [Related]
9. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
Nikiforova MN; Mercurio S; Wald AI; Barbi de Moura M; Callenberg K; Santana-Santos L; Gooding WE; Yip L; Ferris RL; Nikiforov YE
Cancer; 2018 Apr; 124(8):1682-1690. PubMed ID: 29345728
[TBL] [Abstract][Full Text] [Related]
10. Benign call rate and molecular test result distribution of ThyroSeq v3.
Ohori NP; Landau MS; Carty SE; Yip L; LeBeau SO; Manroa P; Seethala RR; Schoedel KE; Nikiforova MN; Nikiforov YE
Cancer Cytopathol; 2019 Mar; 127(3):161-168. PubMed ID: 30561907
[TBL] [Abstract][Full Text] [Related]
11. Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.
Zhu QL; Faquin WC; Samir AE
AJR Am J Roentgenol; 2015 Oct; 205(4):861-5. PubMed ID: 26397337
[TBL] [Abstract][Full Text] [Related]
12. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
13. Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules.
Nishino M; Nikiforova M
Arch Pathol Lab Med; 2018 Apr; 142(4):446-457. PubMed ID: 29336606
[TBL] [Abstract][Full Text] [Related]
14. Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules.
Bose S; Sacks W; Walts AE
Adv Anat Pathol; 2019 Mar; 26(2):114-123. PubMed ID: 30664001
[TBL] [Abstract][Full Text] [Related]
15. Triage of the indeterminate thyroid aspirate: What are the options for the practicing cytopathologist?
Onenerk AM; Pusztaszeri MP; Canberk S; Faquin WC
Cancer Cytopathol; 2017 Jun; 125(S6):477-485. PubMed ID: 28609009
[TBL] [Abstract][Full Text] [Related]
16. Multiplatform molecular test performance in indeterminate thyroid nodules.
Lupo MA; Walts AE; Sistrunk JW; Giordano TJ; Sadow PM; Massoll N; Campbell R; Jackson SA; Toney N; Narick CM; Kumar G; Mireskandari A; Finkelstein SD; Bose S
Diagn Cytopathol; 2020 Dec; 48(12):1254-1264. PubMed ID: 32767735
[TBL] [Abstract][Full Text] [Related]
17. Thyroid nodule molecular profiling: The clinical utility of Afirma Xpression Atlas for nodules with Afirma Genomic Sequencing Classifier-suspicious results.
Babazadeh NT; Sinclair TJ; Krishnamurthy V; Jin J; Heiden KB; Shin J; Berber E; Siperstein A
Surgery; 2022 Jan; 171(1):155-159. PubMed ID: 34924179
[TBL] [Abstract][Full Text] [Related]
18. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
Parajuli S; Jug R; Ahmadi S; Jiang XS
Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
[TBL] [Abstract][Full Text] [Related]
19. Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules.
Ye W; Hannigan B; Zalles S; Mehrotra M; Barkoh BA; Williams MD; Cabanillas ME; Edeiken-Monroe B; Hu P; Duose D; Wistuba II; Medeiros LJ; Stewart J; Luthra R; Roy-Chowdhuri S
Cancer Cytopathol; 2019 Mar; 127(3):146-160. PubMed ID: 30620446
[TBL] [Abstract][Full Text] [Related]
20. Using molecular testing to improve the management of thyroid nodules with indeterminate cytology: an institutional experience with review of molecular alterations.
Glass RE; Marotti JD; Kerr DA; Levy JJ; Vaickus LJ; Gutmann EJ; Tafe LJ; Motanagh SA; Sorensen MJ; Davies L; Liu X
J Am Soc Cytopathol; 2022; 11(2):79-86. PubMed ID: 34627720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]